AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia

RecruitingPhase 2Ages 18 Years - 75 YearsAllMayo Clinic
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Healthy male or non-pregnant, non-breastfeeding female volunteers; * 18-75 years old; * Able to provide written informed consent before participating in the study * Able to communicate adequately with the investigator and to comply with the requirements for the entire study; including the willingness and ability to consume the components of the test meals * Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting, regurgitation) * Patients in the DM group will also require Type 1 or 2 DM of โ‰ฅ 3 years duration; in patients with type 2 DM, the dyspepsia symptoms should have begun or worsened after DM was diagnosed Exclusion Criteria: * Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation, hysterectomy, herniorrhaphy, and limited colonic resection are permissible) * Clinical evidence (including physical exam and EKG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns * Current use of opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase inhibitors, more than one serotonergic medication, and high doses of anticholinergic agents (eg, amitriptyline greater than 50 mg daily). If medically safe, these drugs may be discontinued for four half lives prior to study assessments. * Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect central processing of pain * Bleeding or clotting disorders or medications that increase risk of bleeding from mucosal biopsies * Positive tissue transglutaminase antibodies (TTG), * Pregnant or breast-feeding females * Known intolerance or allergy to eggs * Poor peripheral venous access, if central venous access is not available * Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study * History of Long QT Syndrome or prolonged QT interval (i.e., corrected QT interval \> 480 ms) * Current symptoms of a functional gastrointestinal disorder assessed by questionnaire * Severe vomiting that would preclude tube placement or participation in the study * Structural cause for symptoms by endoscopy within the past 12 months * Patients with gastric pacemakers
๐Ÿ’Š

What it tests

  • Ondansetron 8mg
  • Placebo
๐Ÿ“

Where

1 site
Mayo Clinic in Rochester
Rochester, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy